Short Interest in ImmunoGen, Inc. (NASDAQ:IMGN) Decreases By 13.9%
Short Interest in ImmunoGen, Inc. (NASDAQ:IMGN) Decreases By 13.9%
ImmunoGen, Inc. (NASDAQ:IMGN – Get Rating) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totalling 12,310,000 shares, a decline of 13.9% from the August 15th total of 14,300,000 shares. Based on an average daily trading volume, of 3,140,000 shares, the short-interest ratio is presently 3.9 days.
免疫遺傳公司(納斯達克：IMGN-GET評級)是8月份空頭股數價格大幅下降的接受者。截至8月31日，空頭股數共有12,310,000股，較8月15日的14,300,000股減少13.9%。以日均成交量314萬股計算，目前短息比為3.9天。
ImmunoGen Stock Performance
ImmunoGen股票表現
Shares of NASDAQ:IMGN traded down $0.34 on Friday, hitting $5.04. The stock had a trading volume of 8,902,983 shares, compared to its average volume of 2,536,643. ImmunoGen has a twelve month low of $3.10 and a twelve month high of $7.77. The firm's 50 day moving average price is $5.40 and its 200-day moving average price is $4.83. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -7.30 and a beta of 0.90.
上週五，新浪納斯達克股價下跌0.34美元，至5.04美元。該股成交量為8,902,983股，而平均成交量為2,536,643股。ImmunoGen的12個月低點為3.10美元，12個月高點為7.77美元。該公司的50日移動均線價格為5.40美元，200日移動均線價格為4.83美元。該公司市值為11.1億美元，市盈率為-7.30倍，貝塔係數為0.90。
ImmunoGen (NASDAQ:IMGN – Get Rating) last issued its earnings results on Friday, July 29th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.03). ImmunoGen had a negative net margin of 179.64% and a negative return on equity of 67.02%. The firm had revenue of $14.20 million during the quarter, compared to analyst estimates of $16.18 million. During the same quarter in the prior year, the firm posted ($0.15) EPS. The firm's revenue for the quarter was down 16.0% on a year-over-year basis. As a group, sell-side analysts predict that ImmunoGen will post -0.89 EPS for the current year.
免疫基因(納斯達克：IMGN-GET評級)上一次發佈收益報告是在7月29日(星期五)。這家生物技術公司公佈了該季度每股收益(0.24美元)，低於普遍預期的(0.21美元)和(0.03美元)。免疫基因公司的淨利潤率為負179.64%，淨資產回報率為負67.02%。該公司本季度營收為1,420萬美元，而分析師預期為1,618萬美元。在去年同期，該公司公佈了每股收益(0.15美元)。該公司本季度營收同比下降16.0%。賣方分析師預測，作為一個整體，免疫系統本年度的每股收益將達到0.89歐元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Institutional Investors Weigh In On ImmunoGen
機構投資者對免疫基因的看法
Several institutional investors and hedge funds have recently made changes to their positions in IMGN. RA Capital Management L.P. raised its holdings in shares of ImmunoGen by 7.4% in the first quarter. RA Capital Management L.P. now owns 21,741,458 shares of the biotechnology company's stock valued at $103,489,000 after buying an additional 1,500,000 shares during the last quarter. State Street Corp raised its holdings in shares of ImmunoGen by 32.8% in the second quarter. State Street Corp now owns 18,199,554 shares of the biotechnology company's stock valued at $81,898,000 after buying an additional 4,492,165 shares during the last quarter. BlackRock Inc. raised its holdings in shares of ImmunoGen by 10.6% in the first quarter. BlackRock Inc. now owns 16,432,933 shares of the biotechnology company's stock valued at $78,225,000 after buying an additional 1,569,629 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of ImmunoGen by 2.3% in the first quarter. Vanguard Group Inc. now owns 15,478,516 shares of the biotechnology company's stock valued at $73,678,000 after buying an additional 346,764 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C raised its holdings in shares of ImmunoGen by 332.8% in the second quarter. Deerfield Management Company L.P. Series C now owns 15,020,490 shares of the biotechnology company's stock valued at $67,592,000 after buying an additional 11,549,815 shares during the last quarter. Institutional investors and hedge funds own 95.58% of the company's stock.
幾家機構投資者和對衝基金最近改變了他們在IMGN的頭寸。RA Capital Management L.P.在第一季度增持了免疫遺傳股份7.4%。Ra Capital Management L.P.現在擁有這家生物技術公司21,741,458股股票，價值103,489,000美元，上個季度又購買了1,500,000股。道富銀行第二季度增持了32.8%的ImmunoGen股票。道富集團現在擁有18,199,554股生物技術公司的股票，價值81,898,000美元，在上個季度又購買了4,492,165股。貝萊德股份有限公司在第一季度增持了免疫遺傳的股票10.6%。貝萊德股份有限公司現在持有這家生物技術公司16,432,933股股票，價值78,225,000美元，在上個季度又購買了1,569,629股。先鋒集團(Vanguard Group Inc.)第一季度增持了2.3%的ImmunoGen股票。先鋒集團(Vanguard Group Inc.)目前持有這家生物技術公司15,478,516股股票，價值73,678,000美元，上一季度又購買了346,764股。最後，Deerfield Management Company L.P.Series C在第二季度增持了332.8%的免疫基因股票。Deerfield Management Company L.P.C系列現在擁有這家生物技術公司的15,020,490股股票，價值67,592,000美元，上個季度又購買了11,549,815股。機構投資者和對衝基金持有該公司95.58%的股票。
About ImmunoGen
關於免疫基因
(Get Rating)
(獲取評級)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
免疫基因公司是一家臨牀階段的生物技術公司，開發抗體-藥物結合(ADC)療法來治療癌症。該公司的候選產品包括針對葉酸受體α(FRA)的ADC Mirvetuximab soravtansine，它正處於治療對鉑耐藥的卵巢癌的第三階段臨牀試驗；以及Pivekimab Sunirine，一種針對CD123的ADC，正處於治療急性髓系白血病和原始漿細胞樣樹突狀細胞腫瘤的第二階段臨牀試驗。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- 免費獲取StockNews.com關於免疫基因的研究報告(IMGN)
- 第四季度值得考慮的3家銀行
- 股市：紅海中的三座強國
- 有什麼辦法可以治癒Teladoc股票的問題嗎？
- 沒有人告訴這三隻股票這是下跌的一週
- MarketBeat：回顧一週9/12-9/16
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受《免疫基因日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對免疫系統及相關公司評級的每日簡明摘要。